EBV mRNA Vaccine for the Prevention of EBV-Related Diseases After Allo-HSCT
23. juni 2026 opdateret af: Zhangshan, The General Hospital of Western Theater Command
An Exploratory Study of EBV mRNA Vaccine for the Prevention of EBV-Related Diseases After Allogeneic Hematopoietic Stem Cell Transplantation
The purpose of this clinical trial is to investigate the efficacy of the EBV mRNA vaccine (WGc-0401 injection) in preventing EBV-related diseases after allogeneic hematopoietic stem cell transplantation (allo-HSCT), and to evaluate the safety and efficacy of this vaccine in patients following allo-HSCT.
The main study questions are:
- The incidence of grade III-IV acute graft-versus-host disease (aGVHD) within 100 days, and the occurrence of ≥ grade 3 adverse events (AEs) that are possibly or definitely related to the vaccine, in patients receiving EBV mRNA vaccination after allo-HSCT.
- To determine the optimal biological dose (OBD) of the EBV mRNA vaccine in patients after allo-HSCT among the dose levels of 25μg, 50μg, 75μg, or 100μg.
- EBV-ELISpot levels, the incidence of EBV viremia (EBV DNAemia), the incidence of post-transplant lymphoproliferative disorders (PTLD), disease relapse rate during follow-up, non-relapse mortality (NRM), and immunogenicity indicators (IFN-γ+ T cells, immune cell analysis, cytokine profiles, EBV glycoprotein antigen antibodies).
Participants will:
- Receive three intramuscular injections of the EBV mRNA vaccine on days 30, 44, and 81 after allogeneic hematopoietic stem cell transplantation (d30, d44, d81).
- Be hospitalized for at least 72 hours after each vaccination for close monitoring (with a focus on CRS and aGVHD), and undergo intensive safety assessments throughout the dose-escalation period (at least 28 days).
- Return for clinical visits on days 7 (d37, d51, d88), day 14 (d58), and day 180 (d180) after vaccination for EBV-ELISpot, EBV-DNA quantification, and immunogenicity testing, with continued long-term follow-up to evaluate safety and the persistence of vaccine-induced immune responses.
Studieoversigt
Status
Ikke rekrutterer endnu
Intervention / Behandling
Undersøgelsestype
Interventionel
Tilmelding (Anslået)
20
Fase
- Tidlig fase 1
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiekontakt
- Navn: shan zhang
- Telefonnummer: +8618382430038
- E-mail: 952750480@qq.com
Undersøgelse Kontakt Backup
- Navn: hai yi
- Telefonnummer: +8613699418229
- E-mail: yihaimail@163.com
Studiesteder
-
-
Sichuan
-
Chengdu, Sichuan, Kina
- The General Hospital of Western Theater Command
-
Kontakt:
- shan zhang
- Telefonnummer: +8618382430038
- E-mail: 952750480@qq.com
-
Kontakt:
- hai yi
- Telefonnummer: +8613699418229
- E-mail: yihaimail@163.com
-
Ledende efterforsker:
- shan zhang
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
- Barn
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Ingen
Beskrivelse
Inclusion Criteria:
- Age ≥14 years, regardless of gender;
- Patients undergoing allogeneic hematopoietic stem cell transplantation;
- Voluntary participation in the clinical study and signing of the informed consent form.
Exclusion Criteria:
- History of vaccine allergy;
- Presence of active acute graft-versus-host disease (aGVHD) at screening;
- Severe impairment of cardiac, hepatic, or renal function;
- Body temperature >38°C within 72 hours prior to enrollment;
- Inability to communicate reliably with the investigator or unlikely to comply with study requirements;
- Any other condition deemed by the investigator to make the patient unsuitable for enrollment.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: EBV mRNA Vaccine (WGc-0401)
Drug: EBV mRNA vaccine (WGc-0401 injection) Description: Intramuscular injection of EBV mRNA vaccine (WGc-0401 injection)
|
Intramuscular injection of EBV mRNA vaccine (WGc-0401 injection)
|
|
Ingen indgriben: Observation Group
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of grade III-IV acute graft-versus-host disease (aGVHD)
Tidsramme: Up to 100 days after HSCT
|
Assessed according to the modified Glucksberg criteria (or the MAGIC criteria), with clinical staging comprehensively determined by the attending physician based on the involvement of skin, upper and lower gastrointestinal tract, and liver.
|
Up to 100 days after HSCT
|
|
Incidence of grade ≥3 treatment related adverse events (TRAEs)
Tidsramme: Up to 180 days after HSCT
|
AEs graded per CTCAE v6.0.
Grade ≥3 AEs with causality assessed as possibly, probably, or definitely related to the vaccine are captured.
Systematic AE assessment at each visit covers: local injection site reactions, systemic symptoms (fever, fatigue), laboratory abnormalities (cytopenias, transaminitis), and hypersensitivity.
Causality determined by investigator based on temporal association, biological plausibility, and exclusion of other causes.
|
Up to 180 days after HSCT
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of EBV viremia
Tidsramme: From Day 30 to Day 180 post-transplant
|
EBV-DNA load measured in plasma by quantitative real-time PCR (qPCR).
Abnormal viremia defined as either: (1) ≥10³ copies/mL on two consecutive measurements (with an interval of at least 1 day), or (2) a single measurement ≥10⁴ copies/mL.
|
From Day 30 to Day 180 post-transplant
|
|
EBV-specific T-cell response measured by IFN-γ ELISpot
Tidsramme: Post-transplant days 37, 44, 51, 58, 81, 88, and 180
|
EBV-specific T-cell immune response measured by interferon-gamma (IFN-γ) enzyme-linked immunospot (ELISpot) assay using peripheral blood mononuclear cells (PBMCs) stimulated with EBV peptide pools (e.g., LMP2, EBNA1, BZLF1).
Results expressed as spot-forming cells (SFC) per 2×10⁵ PBMCs.
Positive response defined as ≥25 SFC/2×10⁵ PBMCs and at least 2-fold above negative control.
Samples collected at protocol-specified time points.
|
Post-transplant days 37, 44, 51, 58, 81, 88, and 180
|
|
Incidence of post-transplant lymphoproliferative disorders (PTLD)
Tidsramme: From HSCT (day 0) through 12 months post-transplant
|
PTLD confirmed by tissue biopsy per WHO classification.
EBV status by EBER in situ hybridization.
Subtypes: early lesions, polymorphic, monomorphic, or classic Hodgkin lymphoma-type.
Clinical presentation, sites, and response recorded.
|
From HSCT (day 0) through 12 months post-transplant
|
|
Underlying disease relapse rate
Tidsramme: Day 0 to 12 months post-HSCT
|
Relapse defined as recurrence of primary disease post-HSCT.
Confirmed by bone marrow (≥5% blasts), flow cytometry, cytogenetics/FISH, molecular markers, or extramedullary biopsy/imaging as indicated.
|
Day 0 to 12 months post-HSCT
|
|
EBV vaccine-induced humoral and cellular immune responses
Tidsramme: Pre-vaccination (baseline) and 24h post-vaccination (antibodies/T-cells); pre-vaccination and 6h, 24h post-vaccination (cytokines). Per vaccination dose.
|
Immunogenicity indicators: (1) EBV-specific antibodies (VCA-IgG, EBNA1-IgG) by ELISA; (2) EBV-specific T-cell responses by IFN-γ ELISpot; (3) serum cytokines/chemokines (IL-2, IL-4, IL-6, IL-10, TNF-α, IFN-γ, MCP-1) by multiplex assay.
All samples processed at central lab.
|
Pre-vaccination (baseline) and 24h post-vaccination (antibodies/T-cells); pre-vaccination and 6h, 24h post-vaccination (cytokines). Per vaccination dose.
|
|
Non-relapse mortality (NRM)
Tidsramme: Cumulative NRM at day 100 and 12 months post-HSCT
|
Death from any cause except relapse/progression post-HSCT.
Causes: infection, organ failure, GVHD, second malignancy, hemorrhage, other transplant-related causes.
Deaths without documented relapse included as NRM.
|
Cumulative NRM at day 100 and 12 months post-HSCT
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Anslået)
18. juni 2026
Primær færdiggørelse (Anslået)
31. december 2030
Studieafslutning (Anslået)
31. december 2031
Datoer for studieregistrering
Først indsendt
17. juni 2026
Først indsendt, der opfyldte QC-kriterier
23. juni 2026
Først opslået (Faktiske)
29. juni 2026
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
29. juni 2026
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
23. juni 2026
Sidst verificeret
1. juni 2026
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Andre undersøgelses-id-numre
- EBV mRNA Vaccine-0401
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
JA
IPD-planbeskrivelse
Describe which specific IPD will be shared.
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .